Seroatlas · Human Serome Atlas

SFRP2

Secreted frizzled-related protein 2

Also known as: FRP-2, SARP1, SDF-5, SFRP2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96HF1
Gene: SFRP2
Ensembl: ENSG00000145423
Chromosome: 4
Canonical length: 295 aa
Protein class: Predicted secreted proteins
Subcellular location: Intermediate filaments
Secretome location: Secreted in other tissues

OverviewNCBI Gene

This gene encodes a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. SFRPs act as soluble modulators of Wnt signaling. Methylation of this gene is a potential marker for the presence of colorectal cancer. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

295 residues, UniProt reviewed canonical sequence.

>Q96HF1|SFRP2
     1  MLQGPGSLLL LFLASHCCLG SARGLFLFGQ PDFSYKRSNC KPIPANLQLC HGIEYQNMRL
    61  PNLLGHETMK EVLEQAGAWI PLVMKQCHPD TKKFLCSLFA PVCLDDLDET IQPCHSLCVQ
   121  VKDRCAPVMS AFGFPWPDML ECDRFPQDND LCIPLASSDH LLPATEEAPK VCEACKNKND
   181  DDNDIMETLC KNDFALKIKV KEITYINRDT KIILETKSKT IYKLNGVSER DLKKSVLWLK
   241  DSLQCTCEEM NDINAPYLVM GQKQGGELVI TSVKRWQKGQ REFKRISRSI RKLQC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SFRP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 342 nTPM

Expression across tissuesHPA

Tissue

blood vessel: 342 nTPM
gallbladder: 299 nTPM
urinary bladder: 287 nTPM
esophagus: 200 nTPM
adipose tissue: 176 nTPM
breast: 145 nTPM

Single-cell type

fibroblasts: 702 nCPM
pituicytes/fscs: 61 nCPM
pituitary stem cells: 60 nCPM
fibro-adipogenic progenitors: 25 nCPM
decidual stromal cells: 19 nCPM
mucous neck cells: 16 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hypothalamus: 31 nTPM
hippocampal formation: 28 nTPM
white matter: 28 nTPM
choroid plexus: 27 nTPM
amygdala: 12 nTPM
pons: 12 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.06
gnomAD pLI: 0
gnomAD missense Z: 1.31
DepMap mean gene effect: 0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SFRP2 as an antibody target. Whether an autoantibody or antibody against SFRP2 could matter depends on whether native SFRP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SFRP2 is annotated as secreted, so native SFRP2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label SFRP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...